NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization7.85 mln
Float1.05 mln
Earnings Date06/19/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
8.4
Highly suspicious
Relative Strength
28
/ 100
Underperforming
Debt / Equity
0.01
Debt-free
ROE
-96.49
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Founded in 2002 and headquartered in Geneva, Switzerland, Addex Therapeutics is a pharmaceutical company focused on developing oral drug treatments for neurological conditions. Its most advanced program, Dipraglurant, is being studied in clinical trials for recovery after stroke or brain injury and for managing movement problems caused by Parkinson's disease medication. The company is also advancing additional drug candidates targeting pain, anxiety, addiction, cough, and bladder conditions. Addex works alongside partners Janssen Pharmaceuticals and Indivior PLC to develop and bring these treatments to patients.
